Risk of Multiple Myeloma in Rheumatoid Arthritis: A Meta-Analysis of Case-Control and Cohort Studies

Kaini Shen¹*, Gufeng Xu²*, Qing Wu³, Daobin Zhou¹, Jian Li¹*

¹ Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China, ² Zhejiang University, School of Medicine, Hangzhou, Zhejiang, People’s Republic of China, ³ Division of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona, United States of America

Abstract

**Objectives:** multiple myeloma is a malignant neoplasm of plasma cells mainly affecting elderly patients. Despite the wealth of information available on therapeutic strategies, the etiology and pathogenesis of myeloma remain unclear. In the current study, a meta-analysis was conducted to assess the possible association between rheumatoid arthritis and myeloma.

**Methods:** a literature search was conducted with PubMed, EMBASE and Web of Science for relevant studies published by December 25, 2013. Additionally, we searched annual meeting abstracts of the American Society of Hematology from 2004 to 2013. Only original studies that investigated the association between rheumatoid arthritis and myeloma were included. In total, 8 case-control and 10 cohort studies were identified for analysis.

**Results:** the meta-estimate of the association between rheumatoid arthritis and myeloma was 1.14 (95% CI, 0.97–1.33) overall, with significant heterogeneity among studies. The relationship between myeloma and other autoimmune diseases was additionally examined from available data. Our results showed that myeloma risk is increased 1.31 to 1.65-fold in pernicious anemia and 1.36 to 2.30-fold in ankylosing spondylitis patients.

**Conclusion:** Rheumatoid arthritis does not appear to alter the risk of myeloma, while between-study heterogeneity analyses suggest caution in the interpretation of results. Pernicious anemia and ankylosing spondylitis may be potential risk factors for myeloma development. Future large-scale epidemiological studies with reliable exposure biomarkers are necessary to establish the possible contribution of autoimmune disorders to multiple myeloma.

Introduction

Multiple myeloma (MM) is one of the most common hematologic malignancies with poor prognosis, characterized by neoplastic proliferation of monoclonal plasma cells. The incidence of MM in developed countries is about 5–7 cases per 100,000 individuals [1]. Despite extensive research efforts over the last two decades, the risk factors of MM remain to be established. Numerous case-control and cohort studies to date have suggested that several environmental factors may be associated with the risk of MM, such as ionizing radiation [2], benzene [3] and agricultural occupation [4]. The relationship between autoimmune disease and hematopoietic malignancies was initially postulated in 1964 [5]. However, the issue of whether autoimmune diseases increase the incidence of MM remains controversial.

On the basis of animal models of MM, it is suggested that repeated antigenic stimulation of the immune system plays an important role in MM development [6,7]. A number of studies have confirmed an association of lymphoma with autoimmune conditions [8–12], including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and autoimmune hemolytic anemia, although the underlying pathogenesis is unclear. Similarly, the relationship between MM and autoimmune disease has been a long-term subject of investigation, but inconsistent results have been obtained to date.

The main aim of this meta-analysis was to estimate the comparative risk of developing MM in RA patients versus the general population. Two additional goals were (1) to explore the variation in the association of RA and MM among subgroups of interest and (2) to investigate if there is an association between MM and other autoimmune diseases.

Methods

Search Strategy

A literature search was conducted with PubMed (from January 1, 1951), EMBASE (from January 1, 1955) and Web of Science (from January 1, 1970) using the following search terms: rheumatoid arthritis, autoimmune disease, etiology, epidemiology,
risk factors, multiple myeloma, cancer, malignancy. The final search strategy in PubMed was attached as appendix. The last literature search was performed on December 25, 2013. We also searched annual meeting abstracts of the American Society of Hematology from 2004 to 2013 to identify eligible unpublished data. All references cited in the retrieved articles were additionally reviewed to indentify additional eligible studies. Inclusion criteria were as follows: human participants without limitation of sex or geographic location, case-control or cohort studies, prior medical history of RA as exposure, MM as outcome, studies that reported relative risk (RR), standardized incidence ratio (SIR) or odds ratio (OR) of MM patients with prior history of RA, publication in English. In addition, the selection of cohort studies for inclusion was made regardless of specific RA management strategies. When duplicate reports for the same population and data source were eligible, we chose the original reports with the largest sample size. Case series, case reports, in vitro and animal studies were excluded. Eligibility assessment was performed independently by two reviewers, and disagreements resolved by consensus.

Data Extraction

Two authors performed data extraction independently, and any discrepancies were addressed by discussion and re-evaluation. We obtained information on the author, year of publication, country of origin, source of case, control and cohort, controlled factors, diagnosis criteria and treatment regimen for RA. Cohort size, number of cases, cohort duration, SIR and 95% confidence intervals (CIs) or sufficient data to allow calculation of these numbers were additionally necessary for cohort studies. For case-control studies, the exact numbers of cases and controls by RA, OR and 95% CIs were required. For the purpose of ascertaining the relationship between MM and other autoimmune diseases, related data were recorded, where available, according to the above extraction principles.

The Newcastle-Ottawa Scale (NOS), developed for evaluating the quality of nonrandomized studies [13], was used by two independent reviewers to assess the methodological quality of each study, and the scores subsequently used in subgroup analysis. A score of ≤5 was considered as relative low quality [14].

Statistical Analyses

In case-control studies, OR and 95% CIs for MM risk factors were directly extracted from original research papers or calculated when not provided. The primary outcome for cohort studies was SIR and corresponding 95% CI. In cases where SIRs were not specifically reported, calculations were made from the number of observed MM divided by the number of expected cases in the general population provided by authors, and 95% CI determined using the standard error of the natural logarithm of SIR, estimated from the inverse of the square root of the observed number of cases. The measure of interest was RR, estimated from ORs in case-control studies and SIRs in cohort studies. Since the incidence of MM is low, SIR and OR produce similar estimate of RR, thus we present all results as RR for simplicity [15–17]. Between-study heterogeneity was examined using a chi-square test of heterogeneity and \( I^2 \) measure of inconsistency. P-values less than 0.1 or the \( I^2 \) statistic greater than 50% were considered statistically significant [18]. Under these conditions, data were pooled based on the method of Dersimonian and Laird under a random effects model otherwise under fixed effects model. Two-tailed \( p \leq 0.05 \) was considered statistically significant for all analyses.

To evaluate publication bias, we constructed a funnel plot and applied Begg’s test. Trim and Fill analysis was used to estimate the number of missing studies and their potential effects on outcomes. Sensitivity analyses were additionally conducted to ascertain the robustness of our findings. The influence of RA was examined by excluding studies restricted to elderly patients (≥65 years) or
Table 1. Characteristics of case-control studies enrolled in the meta-analysis.

| Author      | Year | Country       | Sex | Controls | Cases | Controls | OR (95% CI) | Controlled Factors     |
|-------------|------|---------------|-----|----------|-------|----------|-------------|------------------------|
| Pearce NE   | 1986 | New Zealand   | M   | Population | 4 72  | 7 308  | 2.30 (0.60–8.00) | Age, registration year |
| Cohen HJ    | 1987 | USA           | M+F | Hospital  | 62 91 | 203 210 | 0.70 (0.48–1.03) | Age, gender, race, disease status |
| Boffetta P  | 1989 | USA           | M+F | Population | 39 89 | 164 348 | 0.90 (0.60–1.50) | Age, gender, race, residence |
| Lewis DR    | 1994 | USA           | M+F | Population | 64 509 | 241 1 890 | 0.80 (0.60–1.10) | Age, gender, race |
| Vlajinac HD | 2003 | Yugoslavia    | M+F | Hospital  | 12 85 | 5 95  | 2.60 (0.90–7.60) | Age, gender, residence |
| Landgren O  | 2006 | USA           | F   | Population | 7 172 | 9 682  | 2.30 (0.80–6.50) | none |
| Anderson LA | 2009 | USA           | M+F | Population | 263 9 211 | 3 289 119 242 | 1.00 (0.90–1.10) | Gender, year of diagnosis, age at diagnosis |
| Lindqvist EK| 2011 | Sweden        | M+F | Population | 111 19 001 | 567 74 841 | 0.80 (0.60–0.90) | Age, gender, residence |

Abbreviations: RA, rheumatoid arthritis; OR, odds ratio; CI, confidence intervals; M, male; F, female.
doi:10.1371/journal.pone.0091461.t001

Table 2. Characteristics of cohort studies enrolled in the meta-analysis.

| Author       | Year | Country | Sex | Cohort Size | Number of MM | SIR (95% CI) | Follow-up Duration (PY) |
|--------------|------|---------|-----|-------------|--------------|--------------|------------------------|
| Isomaki HA   | 1982 | Finland | M+F | 46 101 | 28 | 2.20 (1.52–3.19) | 213 911 |
| Mellemkjaer L| 1996 | Denmark | M+F | 20 699 | 21 | 1.10 (0.70–1.70) | 144 421 |
| Kauppi M     | 1997 | Finland | M+F | 9 469 | 8 | 1.20 (0.50–2.30) | 65 391 |
| Thomas E     | 2000 | England | M+F | 26 623 | 38 | 1.66 (1.21–2.28) | 151 987 |
| Setoguchi S  | 2006 | USA     | M+F | 7 830 | 19 | 2.00 (1.26–3.12) | 33 410 |
| Herrinton LJ | 2008 | USA     | M+F | 2 982 | 2 | 2.36 (0.28–8.50) | 7 791 |
| Brown LM     | 2008 | USA     | M   | – | 94 | 1.17 (0.94–1.45) | 27 years |
| Parkh-Patel A| 2009 | USA     | M+F | 84 475 | 64 | 0.90 (0.70–1.15) | 405 540 |
| Hemminki K   | 2012 | Sweden  | M+F | 72 309 | 81 | 0.88 (0.70–1.09) | 731 954 |
| Dreyer L     | 2013 | Denmark | M+F | 7 159 | 4 | 1.76 (0.66–4.69) | 24 811 |

Abbreviations: M, male; F, female; MM, multiple myeloma; SIR, standardized incidence ratio; CI, confidence intervals; PY, person years.
--: Not mentioned.
doi:10.1371/journal.pone.0091461.t002
single-sex participants and those that failed to control important confounders. All meta-analyses were conducted with Stata 12.0.

### Results

Abstract evaluation yielded thirty-two potential studies for analysis (Figure 1), of which five [19–23] were excluded, since they

![Forest plot of studies on multiple myeloma development risk in rheumatoid arthritis.](https://doi.org/10.1371/journal.pone.0091461.g002)

**Table 3.** Sensitivity analysis of the association between multiple myeloma and rheumatoid arthritis according to different exclusion criteria.

| Studies included | Studies (N) | RR (95% CI) | p value | \( I^2 \) (%) |
|------------------|-------------|-------------|---------|--------------|
| All studies      | 18          | 1.14 (0.97–1.33) | <0.001 | 71.5 |
| Studies without age restriction of participants* | 17 | 1.09 (0.94–1.27) | <0.001 | 68.7 |
| Studies with both male and female participants* | 15 | 1.11 (0.94–1.32) | <0.001 | 74.1 |
| Studies that controlled for important confounding factors* | 16 | 1.11 (0.95–1.30) | <0.001 | 73.1 |

*Excludes the study by the group of Setoguchi [41].

*Excludes studies by the groups of Pearce [25], Landgren [36] and Brown [45].

*Excludes studies by the groups of Pearce [25] and Landgren [36].

Abbreviations: N, number; RR, relative risk; NS, not significant; CI, confidence interval.

doi:10.1371/journal.pone.0091461.t003
failed to provide sufficient data for calculation. Twenty-three case-control and cohort studies were included after full text assessment. Another two publications [24,25] were incorporated after examining references from the extracted articles. Among the 25 studies, seven [12,26–31] were subsequently excluded for overlap in case or cohort resources. Consequently, our meta-analysis consisted of eight [24,25,32–37] case-control and ten [10,38–46] cohort studies.

All the studies published from 1982 to 2013 were performed in USA or Europe, except one case-control study from New Zealand [25]. There was slight overlap in the patient populations of two studies [38,40] from Finland. Landgren et al. [36] limited the study subjects to women, while the groups of Pearce [25] and Brown [45] mainly focused on the role of prior autoimmune disorders in male MM. The NOS scores varied from 5 to 7 in all case-control studies, with the exception of the reported score of 3 by Landgren and co-workers [36] as a result of unsatisfactory comparability. Since almost all the cohort studies used the expected cancer incidence calculated from national cancer rates as a comparison instead of the non-exposed cohort, NOS scores were relatively low, ranging from 4 to 5.

In the eight case-control studies, OR was all obtained from the published articles or calculated from the numbers of cases and controls by RA. In four cohort studies [10,38,43,44], the SIRs and 95% CIs were estimated from the number of observed MM and expected MM incidence provided by authors, while others were directly extracted from the original article. Only three studies [41,42,44] reported the type of treatment for RA before MM diagnosis. All important information is presented in Tables 1 and 2.

### Table 4. Meta-analysis of multiple myeloma incidence by subgroup.

| Subgroup          | Analyses (N) | RR (95% CI) | p-value | I² (%) |
|-------------------|--------------|-------------|---------|--------|
| Overall           |              |             |         |        |
| Study design      | Cohort (10)  | 1.32 (1.04–1.67) | <0.001  | 72.9   |
|                   | Case-control (8) | 0.92 (0.77–1.11) | 0.031  | 54.6   |
| Publication year  | Before 2000 (7) | 1.10 (0.77–1.59) | <0.001  | 75.7   |
|                   | After 2000 (11) | 1.15 (0.96–1.37) | <0.001  | 71.3   |
| Study quality     | NOS≤5 (13)   | 1.29 (1.02–1.64) | <0.001  | 72.7   |
|                   | NOS>5 (5)    | 0.95 (0.79–1.14) | 0.024  | 64.3   |
| Region²           | USA (9)      | 1.02 (0.86–1.22) | 0.008  | 61.4   |
|                   | Europe (8)   | 1.30 (0.93–1.79) | <0.001  | 80.9   |
| Cohort            |              |             |         |        |
| Publication year  | Before 2000 (3) | 1.48 (0.90–2.45) | 0.047  | 67.3   |
|                   | After 2000 (7) | 1.25 (0.96–1.61) | 0.002  | 72.0   |
| Study quality     | NOS≤5 (9)    | 1.36 (1.02–1.81) | <0.001  | 75.9   |
|                   | NOS>5 (1)    | 1.17 (0.94–1.45) | –      | –      |
| Region            | USA (4)      | 1.25 (0.89–1.77) | 0.017  | 70.4   |
|                   | Europe (6)   | 1.37 (0.95–1.97) | <0.001  | 77.7   |
| Mean follow-up²   | <5 years (5) | 1.63 (0.97–2.74) | <0.001  | 80.4   |
|                   | ≥5 years (4) | 1.17 (0.82–1.66) | 0.015  | 71.2   |
| Case-control      |              |             |         |        |
| Publication year  | Before 2000 (4) | 0.81 (0.65–1.02) | 0.352  | 8.1    |
|                   | After 2000 (4) | 1.02 (0.77–1.36) | 0.021  | 69.1   |
| Study quality     | NOS≤5 (4)    | 1.14 (0.71–1.83) | 0.060  | 59.5   |
|                   | NOS>5 (4)    | 0.88 (0.71–1.10) | 0.046  | 62.5   |
| Region            | USA (5)      | 0.91 (0.74–1.11) | 0.116  | 45.9   |
|                   | Europe (2)   | 1.28 (0.41–3.96) | 0.033  | 77.9   |
| Control type      | Population (6) | 0.92 (0.78–1.10) | 0.088  | 47.8   |
|                   | Hospital (2) | 1.22 (0.34–4.36) | 0.023  | 80.6   |

Abbreviations: N, number; M, male; F, female; RR, relative risk; NOS, Newcastle-Ottawa Scale.

²One case-control study conducted in New Zealand was excluded from analysis.

One study with unknown mean follow-up duration was excluded from analysis.

–: Cannot be calculated.

doi:10.1371/journal.pone.0091461.t004

---

**Table 4. Meta-analysis of multiple myeloma incidence by subgroup.**

**Figure 3. Funnel plot for case-control and cohort studies (dots: original data; squares: filled data).**

doi:10.1371/journal.pone.0091461.g003
The RRs of MM for RA versus non-RA patients overall and by study design was presented (Figure 2). The random-effects pooled RRs for MM were 1.32 (95% CI, 1.04–1.67) for cohort studies and 0.92 (95% CI, 0.77–1.11) for case-control studies. Compared with non-RA patients, RA patients showed an RR of 1.14 (95% CI, 0.97–1.33) regardless of study type, possibly suggesting lack of association between RA and MM. However, overall analysis revealed significant between-study heterogeneity (p = 0.01; I² = 71.5%).

Sensitivity analysis was presented in Table 3. After excluding studies restricted to elderly patients (≥65 years) or single-sex participants and those that failed to adjust important factors, overall RR decreased slightly to 1.09, 1.11 and 1.11, respectively.

To investigate the source of heterogeneity, subset analysis by study design, publication year, study quality, geographic region, control type and average follow-up duration was conducted. Statistical association between RA and MM was only found to be significant in studies with relatively low quality (RR = 1.29, 95% CI, 1.02–1.64) and cohort studies with relatively low quality (RR = 1.36, 95% CI, 1.02–1.81). Overall, in studies with relatively higher quality according to NOS, as well as those published after 2000, RA was not associated with increase in MM risk (RR = 0.95, 95% CI, 0.79–1.14 and RR = 1.15, 95% CI 0.96–1.37, respectively). Notably, subgroup analyses failed to define the reason for heterogeneity (Table 4).

Publication bias in this meta-analysis was suspected as indicated from the funnel plot and Begg’s test (p = 0.081). However, RR values remained similar after Trim and Fill correction for possible missing data (RR = 1.14, 95% CI 0.97–1.33 before Trim and Fill versus RR = 1.09, 95% CI 0.93–1.27 after Trim and Fill) (Figure 3).

The reported relevance of other autoimmune diseases, including pernicious anemia and ankylosing spondylitis (AS), in MM incidence is presented (Figure 4). Patients with pernicious anemia and AS displayed a 1.31- to 1.65-fold and 1.36- to 2.30-fold increase in MM risk, respectively. In contrast, MM development appeared to be unrelated to prior medical history of psoriasis (RR = 0.91, 95% CI, 0.78–1.05), SLE (RR = 1.18, 95% CI, 0.88–1.60), Sjogren syndrome (SS) (RR = 1.22, 95% CI 0.83–1.78) or polymyositis/dermatomyositis (RR = 1.37, 95% CI 0.86–2.17). The between-study heterogeneity analyses were all not statistically significant.

Discussion

Our meta-analysis results suggest that MM seems not more common in patients with a past history of RA, consistent with our sensitivity data. However, subgroup analysis revealed that RA patients are more likely to suffer from subsequent MM in cohort studies (RR = 1.32, 95% CI 1.04–1.67). Information on prior autoimmune diseases in case-control studies was mostly obtained from self-reports through interviews or questionnaires, while in cohort studies, investigators relied mainly on linkage records, which probably attributed to the differences between the two types of studies. Notably, subset analysis confirmed that statistical association between RA and MM was only significant in studies with NOS score < 5, further indicating that RA might not act as risk factor for MM.

A number of studies have explored whether repeated or chronic antigenic stimulation leads to hematopoietic malignancies. Some researchers [31] reported elevated risk for MM in patients with RA, while others [47,48] reached different conclusions. An
antigenic stimulation hypothesis was proposed to explain the excessive risk of MM in patients with autoimmune diseases. Chronic immune stimulation resulting from autoimmune disorders, with its associated lymphocyte activation, tends to induce uncontrolled proliferation of malignant plasma cells, leading to MM [49]. Since no biologic marker has been developed that (an effectively measure lifetime immune stimulation, this theory remains controversial. Meanwhile, evidence from previous studies indicates that increased risk could be a consequence of therapy, rather than the disease itself. For instance, higher risk of non-Hodgkin’s lymphoma and MM has been reported following use of steroids [36,50], which are important for autoimmune disease treatment. Similarly, cytotoxic and immunosuppressive drugs may suppress immunodefense against malignant cells and lead to oncogenesis [51]. Moreover, there may be a common genetic or environmental susceptibility in autoimmune diseases and plasma cell tumors, or undiagnosed MM may manifest with clinical features that mimic connective tissue diseases. Taking our current results and the above studies into account, the credibility of the antigenic stimulation hypothesis is called into question.

Only one cohort study [39] investigated the effect of the duration of follow-up on the risk of MM and determined that the borderline excess of MM was confined to the early 4-year follow-up. Thomas [10] proposed that although increased risk of MM persisted for hematopoietic cancers throughout the follow-up period, the greatest excess was within the first 3 months after hospitalization. These findings could possibly indicate a common etiologic factor for RA and MM, or further prove the association confirmed in above two studies might be resulted from detection bias. With the current common application of anti-TNF drugs, concern has been raised about the risk of developing malignancy related with their use [52]. However, as implied from two studies mentioned earlier [41,44], there was no significant increase in the risk of MM among anti-TNF users. Considering the small number of reports available, further studies are warranted to account for this potential confounder when examining the relationship of autoimmune diseases and MM.

Meta-analysis results revealed that pernicious anemia is another risk factor for MM, consistent with several prior epidemiologic studies [53,54]. The related pathogenesis may involve immune alterations or chromosome abnormalities in the bone marrow of patients with pernicious anemia [54]. On the other hand, vitamin B12 deficiency caused by pernicious anemia may promote MM development by disrupting normal homeostasis for one-carbon metabolism [55]. The lack of association of MM with psoriasis, SLE, SS, and polymyositis/dermatomyositis raises the question of whether oncogenesis is dependent on the type of autoimmune disease. A number of studies evaluating the risk of MM in AS [45] and polymyalgia rheumatic [37] patients have reported positive associations, similar to our assessment of AS and MM. Assumptions such as whether an autoimmune disease resulting in MM is associated with disease activity, amount of autoantibody, and the extent of organ involvement should be examined. Although the current meta-analysis presents a more precise estimate of MM risk in RA patients than individual studies, significant heterogeneity remains a primary limitation of our study. Subgroup analyses failed to determine the source of heterogeneity. The diversity of subject sources and study methodologies may have led to inconsistencies. One such example is the study by Boffetta [33] including 282 patients that died from MM, meaning that they were likely to suffer from more severe diseases and past medical history obtained from their family members was possibly incomplete. Similarly, another study [41] was restricted to subjects older than 65 years whose disease spectrum may be distinct from that of the general population. The variable proportions of races in different studies may additionally contribute to significant heterogeneity. Moreover, misclassification of patients may have occurred in case-control studies, since no consistent diagnosis criteria were applied by investigators and most enrollments were dependent on reports and certificates, rather than specific laboratory data, similar to enrollment in cohort studies. As indicated in cohort studies, RA patients may develop MM after more than 20 years, in which case recall bias may exist in case-control studies.

Another limitation of this study is that certain articles had to be excluded, since no data on MM and RA were available, although their relationship was evaluated. Exclusion of such studies may have led to results bias. In spite of this, the possible bias might not be so evident, since why these data were not reported mostly lied in that authors found no specific association between RA and MM. Although publication bias was borderline significant as indicated by Begg’s test, adjustment for possibly missing manuscripts yielded similar results, strongly supporting the robustness of our analyses.

Conclusion

Despite its limitations, our meta-analysis provides novel evidence for increased MM development risk in AS and pernicious anemia, although the underlying pathogenesis remains controversial. Notably, RA does not appear to alter the risk of MM, while between-study heterogeneity suggested caution in the interpretation of results. Further large-scale longitudinal studies containing details of risk factors and treatment information are necessary to determine the pathophysiological mechanism linking autoimmune diseases and MM. Moreover, identification of reliable exposure biomarkers of immune stimulation would be significantly beneficial.

Supporting Information

Appendix S1 Search strategy for PubMed. (DOCX)

Checklist S1 PRISMA 2009 Checklist for current meta-analysis. (DOC)

Author Contributions

Conceived and designed the experiments: KNS GFX QW DBZ JL. Performed the experiments: KNS GFX QW DBZ JL. Analyzed the data: KNS GFX QW JL. Contributed reagents/materials/analysis tools: JL. Wrote the paper: KNS GFX QW.

References

1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, et al. (2004) Incidence of multiple myeloma in Olmsted County, Minnesota - Trend over 6 decades. Cancer 101: 2667–2674.
2. Cuzick J (1981) Radiation-Induced Myelomatosis. New England Journal of Medicine 304: 204–210.
3. Infante PF (2006) Benzene exposure and multiple myeloma - A detailed meta-analysis of benzene cohort studies. Living In a Chemical World: Framing the Future In Light Of the Past 1076: 90–109.
4. Blair A, Zahn SH,Pearce NE,Heinemann EF,Fraumeni JF (1992) Clues to Cancer Etiology from Studies of Farmers. Scandinavian Journal of Work Environment & Health 18: 209–215.

PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e91461
Hemminki K, Li X, Sundquist K, Sundquist J (2008) Cancer risk in hospitalized

Eriksson M (1993) Rheumatoid arthritis as a risk factor for multiple myeloma: a

Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, et al. (2009)

Doody MM, Linet MS, Glass AG, Friedman GD, Pottern LM, et al. (1992)

Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast
cancer: A meta-analysis. International Journal Of Cancer 121: 856–862.

Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, et al. (2006)

Radl J, Croese JW, Zurcher C, Van den Enden-viveen MH, de Leeuw AM (1988) Animal model of human disease. Multiple myeloma. Ann J Pathol 132: 593–597.

Snedley KE, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, et al. (2008)

Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph consortium. Blood 111: 4929–4938.

Mellemkjaer L, Pfeiffer RM, Engels EA, Gridley G, Wheeler W, et al. (2008) Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin’s lymphoma. Arthritis and Rheumatism 50: 657–666.

Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. International Journal of Cancer 88: 497–502.

Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, et al. (2006) Autoimmunity and susceptibility to Hodgkin lymphoma: A population-based case-control study in Scandinavia. Journal of the National Cancer Institute 98: 1321–1330.

Gridley G, McLaughlin JK, Elsdon A, Klæreskog L, Adamo HO, et al. (1993) Incidence of Cancer among Patients with Rheumatoid-Arthritis. Journal of the National Cancer Institute 85: 307–311.

Wells G, Shea B, O’Connell D, Peterson J, Welch V, et al. (2011) The

 Greenland S (1987) Quantitative Methods In the Review Of Epidemiologic

Lea AJ (1964) An association between the rheumatic diseases and the reticuloses. The British Journal of Rheumatic Diseases 64: 1414–1420.

Hemminki K, Liu XD, Forsti A, Ji JG, Sundquist J, et al. (2012) Effect of
treatment with methotrexate. Arthritis & Rheumatism-Arthritis Care &
Research 59: 794–799.

Chen YJ, Chang YT, Wang CB, Wu CY (2011) The Risk of Cancer in Patients With Rheumatoid Arthritis A Nationwide Cohort Study in Taiwan. Arthritis and Rheumatism 65: 352–358.

Anderson LA, Gaddis S, Morton LM, Landgren O, Pfeiffer R, et al. (2009) Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. International Journal of Cancer 125: 398–405.

Pearce NE, Smith AH, Howard JK, Steppard RA, Giles GH, et al. (1986) Case-Control Study of Multiple-Myeloma and Farming. British Journal of Cancer 54: 493–500.

Eriksson M (1993) Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study. Eur J Cancer 29A: 259–263.

Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, et al. (2006) Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. International Journal of Cancer 118: 3093–3098.

Asking J, Foret CM, Baechkland E, Brandt L, Backlin C, et al. (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Annals of the Rheumatic Diseases 64: 1414–1420.

Hemminki K, Li X, Sundquist K, Sundquist J (2008) Cancer risk in hospitalized
rheumatoid arthritis patients. Rheumatology 47: 698–701.

Isoikami HA, Hakulinen T, Joutsenlaiti U (1978) Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31: 691–696.

Hakulinen T, Isoikami H, Knekt P (1985) Rheumatoid-Arthritis and Cancer Studies Based on Linking Nationwide Registries in Finland. American Journal of Medicine 78: 29–32.

Cohen HJ, Bernstein RJ, Gruffeferman S (1967) Role of Immune Stimulation in the Etiology of Multiple-Myeloma - a Case Control Study. American Journal of Hematology 24: 119–126.

Boffetta P, Stellman SD, Garfinkel L (1989) A Case-Control Study of Multiple-
Myeloma Nested in the American-Cancer-Society Prospective-Study. Interna-
tional Journal of Cancer 45: 554–559.

Levis DR, Pottet LM, Brown LM, Silverman DT, Hayes RB, et al. (1994) Multiple-Myeloma among Blacks and Whites in the United-States - the Role of Chronic Antigenic-Stimulation. Cancer Causes & Control 5: 529–539.

Vijjan DC, Pekmezovic TD, Adanja BJ, Marinovic JM, Kanazir MS, et al. (2003) Case-control study of multiple myeloma with special reference to diet as risk factor. Neoplasma 50: 79–83.

Landgren O, Zhang YW, Zahm SH, Insipcz P, Zheng TZ, et al. (2006) Risk of multiple myeloma following monoclonal gammopathy and renal failure: A case-
case-control study in Connecticut women. Cancer Epidemiology Biomarkers &
Prevention 15: 2342–2347.

Landquist EK, Goldin LR, Landgren O, Bilkmar C, Mellyquist UH, et al. (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118: 6284–6291.

Isoikami HA, Hakulinen T, Joutsenlaiti U (1982) Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 41: 349–456.

Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, et al. (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A: 1753–1757.

Kappli M, Pukkala E, Isoikami H (1997) Elevated incidence of hematologic malignancies in patients with Sjogren’s syndrome compared with patients with rheumatoid arthritis (Finland: Cancer Causes Control 8: 201–204.

Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, et al. (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54: 2737–2746.

Herrinton LJ, Liu L, Shoo S, Mines D (2008) Risk of lymphoproliferative cancer among patients with severe rheumatoid arthritis, 1996–2002. Ann Rheum Dis 67: 574–575.

Parikh-Patel A, White RH, Allen M, Cress R (2009) Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 20: 1001–1010.

Dreyer L, Mellemkjaer L, Andersen AR, Bennett P, Poulsen UE, et al. (2013) Incidences of overall and site specific cancers in TNF alpha inhibitor treated patients with rheumatoid arthritis and other conditions - a follow-up of the DANBIO Registry. Annals of the Rheumatic Diseases 72: 79–82.

Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gammapathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111: 3380–3389.

Hemminki K, Liu XD, Forsti A, Ji JG, Sundquist J, et al. (2012) Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. Journal of Hematology & Oncology 5.

Gramenzi A, Butino I, Davanbu N, Negri E, Franceschi S, et al. (1991) Medical History and the Risk of Multiple-Myeloma. British Journal of Cancer 63: 769–772.

Cucick J, Destavalia BL (1989) Autoimmune Disorders and Multiple-Myeloma. International Journal of Epidemiology 18: 283–283.

Symmons DPF (1988) Neoplasmia in Rheumatoid-Arthritis. Journal of the Rheumatism 5: 497–502.